NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals Inc (NGM) priced its initial public offering on Apr 4, 2019 at $16.00 per share, raising $106.7M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.04B. Goldman Sachs was lead-left underwriter, joined by Citigroup and TD Cowen. Cooley advised the company and Davis Polk advised the underwriters.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for cardio-metabolic, liver, oncologic and ophthalmic diseases. Its most advanced candidate, NGM282, is wholly owned and is being advanced into Phase 2b development for non-alcoholic steatohepatitis (NASH).

Status

IPO

Ticker

NGM

Exchange

Nasdaq Global Select

Priced

Apr 4, 2019

IPO price

$16.00

Raised

$106.7M

Market cap at IPO price

$1.04B

First filed

Sep 28, 2018

Underwriters

Goldman Sachs, Citigroup and TD Cowen

Company counsel

Cooley

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.